| External factors: | Doxorubicin |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | Flow cytometry//SA-β-gal activity assay |
| Description: | Drug effect on the cell cycle was determined by flow cytometry. The population of cells in the S-phase decreased, whereas those in the G2-M increased and reached a peak at 10-7M doxorubicin.This was associated with an increased activity of the senescence-associated β galactosidase (SA-β-Gal), confirming that the cells were in senescence. |
| Regulatory pathway: | p21 |
| R-EF-Pathway: | Upregulation |
| Official symbol(s): | CDKN1A |
| Pathway experiment: | Western blot//RT-PCR |
| Pathway description: | Expression of p21/WAF1 was maximal at 10-7M doxorubicin followed by a sharp decrease starting at 5X10-7M.However, examination of p21/WAF1 expression by RT-PCR indicated that although this may be the case at intermediate drug concentrations (such as 5X10-7M doxorubicin), high drug concentrations seemed to exert an inhibitory effect p21/WAF1expression at the message level. |
Annotation: